NCT03353298

Lowering Uric Acid in Live Kidney Donors

A Randomized, Double-blind, Placebo-controlled, 9-month, Parallel Group Study of Allopurinol to Reduce Left Ventricular Mass in Living Kidney Donors (AL-DON)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 71 (actual)
• Sponsor: Oslo University Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Recently there was described an increase in left ventricular mass after kidney donation. It is uncertain whether this is reversible or not. Allopurinol lowers uric acid in the blood and is normally indicated for gout, but studies have showed that it also can reduce the thickness of the left ventricle of the heart in people with heart- and kidney disease. The investigators wish to give allopurinol or placebo to kidney donors based on randomization and investigate if this has the same effect on kidney donors. The investigators are assessing this by performing a cardiac MRI at baseline and after 9 months of treatment. In addition the investigators wish to see if allopurinol can have beneficial effects on blood pressure and insulin sensitivity as well.

Conditions

• Renal Transplant Donor of Left Kidney
• Renal Transplant Donor of Right Kidney

Interventions

Type	Name	Description
DRUG	Allopurinol 300 mg	Allopurinol oral tablets 300 mg given to participants once daily for 9 months
DRUG	Placebo Oral Tablet	placebo oral tablets given to participants once daily for 9 months

Timeline

• Start date: 2018-01-17
• Primary completion: 2020-09-25
• Completion: 2020-09-25
• First posted: 2017-11-27
• Last updated: 2021-02-24

Locations

1 site across 1 country: Norway